Skip to content

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.

Pfizer share price: what to expect from Q4 results

In this article we find out what we can expect from the upcoming Pfizer results, how they could affect the Pfizer share price as well as how to trade the earnings.

Vaccine Source: Bloomberg

When is Pfizer’s earnings date?

The Pfizer earnings release date is scheduled for the 2 February 2021. The results will cover the groups fourth quarter (Q4) and full year earnings.

Pfizer results preview: what does the Street expect?

Consensus estimates for Pfizer’s fiscal year 2020 (FY20) revenue, profit and earnings per share (EPS) values find confluence with the lower end of the company’s guidance in the last quarter. The forecasted range for the group's FY20 revenue is between $48.8 and $49.5 billion, a decline from the FY19 revenue figure of $51.75 billion. The FY20 EPS (adjusted and diluted) figure for Pfizer is expected to be realised at between $2.88 to $2.93, from $2.95 realised in the previous year (FY19).

How to trade Pfizer Q4 results

The two graphics below provide traders with both a retail short term view on the stock, as well as an institutional longer-term view on the Pfizer share price, as to how market participants are positioned ahead of the Q4 earnings release.

Source: IG charts

A Thomson Reuters poll of 21 analysts maintain a long-term average rating of ‘hold’ for Pfizer (as of 1 February 2021), with one of these analysts recommending a strong buy, five recommending a buy, 14 hold, one sell and zero strong sell recommendations on the stock.

Source: IG charts

From a retail trader perspective (as of 1 February 2021), 99% of IG clients with open positions on the Pfizer expect the share price to rise over the near term, while 1% of IG Clients with open positions expect the Pfizer price to fall.

Pfizer share price: technical analysis

Pfizer chart Source: IG charts
Pfizer chart Source: IG charts

The Pfizer share price continues to trade in a rangebound environment which has been in place since July last year (2020). This technical trading range is considered between levels 35.20 (support) and 39.30 (resistance).

In the short term, we see the Pfizer share price now approaching the support of the aforementioned range at 35.20. Range traders might hope for a bullish price reversal at or near this level to find long entry, targeting a move back towards historical resistance at 39.30. Should the share price instead continue to fall and trade below the 33.40 level, the rangebound price environment would require reassessment.

In summary

  • Pfizer Q4 results are scheduled for release on the 2 February
  • Group revenue and EPS for FY20 are expected to have declined from the previous year
  • The average long-term broker rating for Pfizer is ‘hold’
  • The majority of IG clients with open positions on Pfizer expect the price to rise in the near term
  • A technical analysis view on the Pfizer share price shows a short- to medium-term rangebound price environment

This information has been prepared by IG, a trading name of IG Markets Ltd and IG Markets South Africa Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Seize a share opportunity today

Go long or short on thousands of international stocks.

  • Increase your market exposure with leverage
  • Get spreads from just 0.1% on major global shares
  • Trade CFDs straight into order books with direct market access

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Monday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.